Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 30Unknown 14Terminated 6Not yet recruiting 5Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 549Neoplasms 384Carcinoma, Non-Small-Cell Lung 319Colorectal Neoplasms 290Lung Neoplasms 239Prostatic Neoplasms 219Carcinoma, Hepatocellular 212Stomach Neoplasms 158Pancreatic Neoplasms 151Leukemia, Myeloid, Acute 139Multiple Myeloma 130Uterine Cervical Neoplasms 127Recurrence 116Rectal Neoplasms 112Ovarian Neoplasms 105Neoplasm Metastasis 104Squamous Cell Carcinoma of Head and Neck 97Head and Neck Neoplasms 89Esophageal Neoplasms 85Triple Negative Breast Neoplasms 84Glioblastoma 80Small Cell Lung Carcinoma 79Endometrial Neoplasms 79Colonic Neoplasms 78Brain Neoplasms 78Melanoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Glioma 62Motor Activity 60

Interventions

tislelizumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Hypersensitivity × Clear all
NCT07572162 2026-05-07

Post-market Safety Study of LUMISIGHT

Lumicell, Inc.

Not yet recruiting
1,500 enrolled
Breast

Anaphylaxis, Breast Neoplasms, Drug Hypersensitivity, Hypersensitivity

NCT07478315 2026-03-17

IMPOWER-QoL: IMPact Of Discontinuing Premedication for WEekly Paclitaxel on bReast Cancer Patient's Quality Of Life

Charles LeMoyne Hospital

Phase NA Not yet recruiting
50 enrolled
Breast

Breast Neoplasms, Hypersensitivity

NCT07420036 2026-03-03

SFB6-ZN01 PET

Zhongnan Hospital

Phase EARLY_PHASE1 Not yet recruiting
98 enrolled

Hypersensitivity, Neoplasms

NCT07209774 2025-10-07

Healthspan Connect Programme of Research

King's College London

Not yet recruiting
100,000 enrolled

Psychological Well-Being, Hypersensitivity, Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Shandong University

Not yet recruiting
200 enrolled
Breast

Hypersensitivity, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡